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that setting arbitrary benchmarks based on empirical observation of compara-
tive EU countries is incorrect due to wide inconsistencies over pharmaceutical 
distribution.
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HTA Informed PrIce negoTIATIons: cosT sAvIngs To THe HeAlTH PAyer 
In IrelAnd
McCullagh L.M.1, Tilson L.1, Adams R.1, Barry M.2
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2HSE Medicines Management 
Programme, Dublin, Ireland
Objectives: In Ireland, the reimbursement decision process involves the Marketing 
Authorisation Holder (MAH) submitting a Health Technology Assessment (HTA) dos-
sier to the National Centre for Pharmacoeconomics (NCPE). The NCPE evaluates 
this dossier and submits a reimbursement recommendation to the Health Service 
Executive (HSE) (the decision maker). Along with Cost-Effectiveness and Budget 
Impact analyses, the decision maker considers other criteria in determining the 
health benefit of an intervention. Those interventions which are not deemed cost 
effective at a threshold of € 45,000/QALY may proceed to HTA informed HSE-MAH 
price negotiations. The aim of this study was to estimate the potential annual cost 
savings (reduced potential budget impacts) to the HSE as a consequence of HTA 
informed price negotiations. MethOds: All NCPE assessments received over a 2 
year period were reviewed. Interventions were included if initially they had not been 
recommended for reimbursement, but had subsequently been reimbursed after 
HTA informed price negotiations. The potential total annual cost saving to the HSE 
(difference between the original Gross BI (submitted price) and the revised Gross 
BI (negotiated price) was estimated. The respective MAH BI models were used for 
these analyses. Results: Eight interventions fitted the inclusion criteria; all were 
classified as either oncology drugs or drugs for orphan diseases. When all such 
drugs are considered, it is estimated that the cost savings to the HSE, as a result of 
HTA informed price negotiations is over € 19 million per annum. cOnclusiOns: 
In Ireland, HTA informed price negotiations lead to considerable cost savings to 
the Health Payer.
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Access To non communIcAble dIseAse medIcInes In IndIA: A 
comPArATIve AnAlysIs of sTATe level PublIc ProcuremenT dATA
Chokshi M.1, Farooqui H.H.2
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Objectives: - To assess access to NCD medicine in India using public drug procure-
ment data. MethOds: - State procurement data was used to calculate, total and per 
capita value of procurement towards purchase of essential medicines. ABC analysis 
was performed to identify priority medicines that together account for 80% of total 
expenditure (Category A items). The proportion of NCD medicines among category A 
items was then estimated. Finally, the efficiency of the system was captured through 
comparative price analysis of procurement price to International Reference Price 
(IRP). Results: - Out of the 91 NCD medicines on WHO list of essential medicine, 
states were procuring 40 to 87 NCD medicines. In addition, the share of NCD pro-
curement value to total procurement value was in range of 1.32% to 37%. Similarly, 
the annual per capita spending was in range of 0.1 to 103 Indian Rupees (INR). 
The procurement prices across all the states were lower than the international 
reference price. The retail market prices were between 45%-3600% higher than the 
state procurement prices, and were higher on average by 6 times of international 
reference price. The defined daily dose estimates were not uniform for all ATC. The 
most neglected category among all ATC’s was mental health, in the range of 0.020-
56.688 DDD per 1000. cOnclusiOns: - There is limited access to NCD medicines 
in public health system in selected Indian states.
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consTrucTIng A comorbIdITy Index AccordIng To Iso-resource 
consumPTIon
Sicras-Mainar A.1, Navarro-Artieda R.2
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Objectives: To construct a comorbidity index according to iso-consumption of 
health resources and their associated costs in routine clinical practice. MethOds: 
We made a multicentre study through review of computerized medical records. 
The study population consisted of patients assigned to seven primary care centres, 
two acute care hospitals and one social health centre, allmanaged by Badalona 
ServeisAssistencials SA. The following variables were analysed: age (0-100 years), 
sex, comorbidity (chronic diagnoses) and direct health care costs. We estimated 
the resource use and gross health care costs attributed to all patients requiring 
health care in 2013. Subsequently, an expert panel identified the most-prevalent 
chronic diseases (ICD-9). Subgroups were established according to age and number 
of chronic comorbidities. The main variables and comorbidities associated with 
the costs were identified using a multivariate model. This allowed a total score to 
be developed for each patient. Statistical analysis: Spearman’s correlation coef-
ficient, multiple logistic models and linear regression were used. A value of p < 0.05 
was identified as significant. Results: We recruited 103,764 patients (86.5% of the 
total). Mean age was 43.1 (23.9) years and 52.4% were female. The mean unit cost 
was € 836.9 (2032). The gross cost was associated with age (r = 44.8) and comor-
bidity (r = 0.512). The final score was obtained from the logistic model. The score 
obtained showed a good correlation with age (r = 81.8), comorbidity (r = 0.939) 
and the cost of health care (r = 0.696). The index obtained explained 44.7% of the 
gross cost. The index was better adapted to the adjusted costs. We describe the 
disaggregated results and the results according to levels of comorbidity (healthy, 
low, medium, high). cOnclusiOns: The comorbidity index obtained was shown 
to be a simple potential predictor of the cost of care and may be applied in routine 
clinical practice.
PHP93
AssessIng AssessmenT: does HeAlTH TecHnology AssessmenT do ITs 
Job of conTrollIng cosTs WITHouT comPromIsIng QuAlITy?
Armstrong S.1, Garfield S.2
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Objectives: The pace of innovation in health care has facilitated gains in life 
expectancy, but at a tremendous cost. Rational use of limited health care resources 
remains one of the greatest challenges in health care worldwide. This analysis 
sought to compare health care spending and health outcomes in countries with 
and without formal health technology assessment programs. MethOds: Data 
was collected on health care spending from 1990-2012 in European countries with 
and without HTA and compared to the United States, which eschews any formal 
evaluation of comparative or cost effectiveness. Measures of health outcomes were 
considered, including life expectancy and overall mortality. The impact of popula-
tion age, tobacco use and obesity rates on health outcomes were considered. Lastly, 
the number, content and methodology of HTA publications in countries with HTA 
were assessed. Results: The majority of HTA evaluations have focused on phar-
maceuticals. Countries with established HTA had lower spending on pharmaceu-
ticals, but not always lower overall health care spending, while maintaining or 
improving health outcomes relative to non-HTA countries. The United States had 
the highest rate and annual increase in rate in pharmaceutical spending as well as 
overall health care spending, with the worst health care outcomes in countries ana-
lyzed. cOnclusiOns: The incorporation of formal health technology assessment as 
part of overall health care decision making appears to assist in controlling the rise 
in health care spending, particularly drug spending. While better health outcomes 
in life expectancy and mortality were found in HTA versus non-HTA countries, 
correlation versus causality can only be considered at this point. Systematic use of 
HTA on both pharmaceutical and non-pharmaceutical interventions may help to 
control overall health care spending.
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Yenilmez F.B.1, Kockaya G.2
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Objectives: Health Transformation Program was started at year 2002 by Ministry of 
Health (MoH) in Turkey. Today, Turkey has a well established health system mostly 
dominated by government on health care provider and payer. The program allows 
the patient access to all drugs. There was an increasing trend for the pharmaceu-
tical consumption in years depending on the taken policies as other health care 
services. The aim of this study is to review an analysis for the new drug release 
prices for Turkey in the recent years. MethOds: The data was obtained from the 
last price list of each calender year published by MoH for the years between 2009-
2014. The year 2014 year data limited with the first quarter (Q1). The data classified 
in three groups which were; over 100 TL, over 1000 TL and over 10000 TL. All the 
result were based on ex-factory prices. A descriptive analysis was conducted on 
the price lists with the number of the products, maximum and average ex-factory 
prices. Results: The numbers of new released products over 100 TL were; 1, 7, 58, 
36 and 52 in the years 2009, 2010, 2011, 2012 and 2013, respectively. The numbers 
of new released products over 1000 TL were; 0, 1, 10, 11 and 13 in the years 2009, 
2010, 2011, 2012 and 2013, respectively. The highest ex-factory prices were 739 TL, 
1117 TL, 4066, 72 TL, 5781, 05 TL, 22791, 55 TLand 36577, 33 in the years 2009, 2010, 
2011, 2012 and 2013, respectively. The average ex-factory prices were 178, 98 TL, 329, 
28 TL, 214, 36 TL, 312, 93, 497, 44 TL and 612, 85 TL in the years 2009, 2010, 2011, 2012, 
2013 and 2014Q1 respectively. cOnclusiOns: It was shown that the number of 
high prices drugs, the highest price and the average price of the new drugs were 
increased year by year. Increased patient access may encoruage pharmaceutical 
companies to enter the Turkish market with their innovative drugs which have high 
price tag compared to regular drugs.
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seTTIng TArgeTs for PublIc sPendIng under eu-Imf AssIsTAnce To 
PorTugAl - THe cAse of HeAlTH cAre And PHArmAceuTIcAls
Rocha L., Fernandes C., Viana R.
Novartis Farma-Produtos Farmacêuticos S.A., Portugal, Porto Salvo, Portugal
Objectives: The 2008 global financial crisis hit Portugal strongly culminating 
in request financial assistance from European Union and International 
Monetary Fund on 17th May of 2011. In addition, Portuguese economy had already 
before 2008 a decreasing real growth rate of GDP, stagnant from early in the dec-
ade, and an increasing external deficit. Health care measures represented a key 
area within the assistance program. Specific targets were set for public spend-
ing in pharmaceuticals in order to align with EU average at 1.25 and 1.0 percent 
of GPD for 2012 and 2013, respectively. The aim of our study was to demonstrate 
that GDP targets was a political decision not supported by evidence, techni-
cally inaccurate, created a hurdle and equity asymmetries for patients access to 
medications, as well as jeopardized the future sustainability of Pharmaceutical 
sector. MethOds: We analyzed health, pharmaceuticals and medicines public 
spending EU benchmark in real terms, GDP ratio and per capita. We also revise 
the System of Health Accounts methodology and conceptual framework of 
International Classification of Health Accounts. OECD definitions, sources and 
methods were also studied. Results: Despite the efforts to improve the com-
parability across countries through common and better information framework 
of greater relevance for policy concerns, we observed that such approach is not 
recommended. For a more comprehensive understanding of health spending in 
relation to GDP ratio, it should be considered together with health spending per 
capita. Portugal comparisons are an OECD example for this rational. Importantly, 
OECD measures of pharmaceutical spending exclude in-patient (hospital) spend-
ing. In addition, pharmaceuticals definition is broader than prescription medicines 
only. cOnclusiOns: Important political decisions were taken assuming pharma-
ceuticals and prescription medicines as the same concept. Here, we demonstrate 
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tical expenditure per capita Δ x2009-2012= -37,6%, x2012= 282 € , rebate from pharma-
ceutical companies Δ x2009-2012= +364,1%, net public pharmaceutical expenditure 
Δ x2009-2012= -42,3%, x2012= 2.88 mil € , net public pharmaceutical expenditure per 
capita Δ x2009-2012= -43%, x2012 = 253 € , net public pharmaceutical expenditure as % 
of GDP Δ x2009-2012= -36,3% and in 2012 they constituted 1,4% GDP. Price changes of 
medicines Δ x2005-2011= -17,8%, Δ x2010-2011= -10,7%. cOnclusiOns: Interventions 
implemented in 2010 had according presented parameters a great impact on effec-
tiveness of Health care and Pharmaceutical sector and this improvement will con-
tinue for a few years more. The betterment of Health care and Pharmaceutical sector 
might help to lower the public debt and recover economic credibility of Greece.
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APPlIcATIon To exPensIve drugs
Siorat V.1, Degrassat-Théas A.1, Paubel P.2, Parent de Curzon O.1, Sinègre M.1
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Objectives: Hopital’s attractiveness can impact the number of inpatients, and so 
health care expenditures. The objective is to identify parameters related to patients 
or drugs, wich influence the proportion of inpatients not residing in the hospital’s 
region, in order to better understand expensive drug expenditures. MethOds: A 
database on expensive inpatient drugs listed on a national formulary was set up, 
with information related to drugs -from National and European Health authori-
ties- and patients -from our university hospital centre’s database (UHC) of the 
Paris region. A censored regression model, Tobit model, was developed in which 
the dependent variable was, for each drug, the ratio of the number of inpatients not 
residing in the Paris region, on the total number of inpatients receiving this drug. 
Explanatory variables were related to drugs and to patients. All statistical tests 
were run in Stata/IC13®. Results: During 2012, 526 091 doses -of the 113 drugs 
list- are administered to 30 499 UHC inpatients. 13% of inpatients come from off 
the Paris region. According to the Tobit model, three variables positively impact the 
ratio (innovative status, percentage of women and Diagnosis Related Group coded 
as severe) and three negatively (orphan designation, percentage of patients over 
65 years old, biological origin). Therapeutic classes and Major Diagnostic Categories 
also impact significantly the ratio according to the statistic class. For instance, 
innovative status, defined by a market authorization granted in the five last years 
and a high level of improvement in actual benefit, improves the ratio of 8.6 points. 
To benefit from the most innovative treatments, patients tend to be cared in UHC’s 
hospitals. cOnclusiOns: This study represents the first step of modelling signifi-
cant determinants of hospital’s attractiveness for patients. It focuses, quite uniquely, 
on patients and drugs factors, and could be extended to other variables.
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economIc ImPAcT of clInIcAl reseArcHes To THe reseArcH cenTers 
And reImbursemenT sysTems In Turkey
Kockaya G.1, Daylan Kockaya P.2, Demir M.3, Uresin A.Y.3
1Health Economics and Policy Association, Ankra, Turkey, 2Zirve University, Gaziantep, Turkey, 
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Objectives: Clinical researches are an important tool for the improvement of 
medicine and significant economic value. The aim of this study was to investigate 
the economic impact of clinical researches to the research centers and reimburse-
ment system in Turkey. MethOds: Budget of clinical trials were calculated from 
the raw data of the Report of Istanbul Medical Faculty Clinical Researches (ITFKAR) 
between years 2006-2010. In addition, the possible cost of the drugs that were used 
in the clinical researches for SGK was calculated for showing the cost of medicines 
acquired with clinical researches. It has been accepted that predicted budgets of 
reviewed files were spent for research. Similarly, it has been accepted that the num-
ber of patients was not changed during the studies. Thus, approved budgets could 
be accepted as drug investment of the approval year. For the calculation of drug 
costs, discounted reimbursement figures of Social Security Administration (SGK) 
for licenced products were used. If not licenced and imported via Turkish Chamber 
of Pharmacists, the prices of abroad drug list of SGK were used. Calculations were 
performed with the drug prices for the year 2013. Results: The average of drug cost 
savings per patient with participation to the clinical research and clinical research 
investment per patient were calculated as US$ 21.649 and US$ 4.879. It could be said 
that total budget of sponsored pharmaceutical researches was US$107 million and 
the government had a saving close to US$ 311.096.130 due to not reimbursing the 
cost of drugs of the patients who were included to the clinical researches in Turkey 
depending on the analysis. cOnclusiOns: However study is based on assump-
tions, the findings are unique for the literature. The health policy makers can take 
account the study of the policy improvements about clinical trials in Turkey.
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PHArmAceuTIcAl develoPPemenT: AfrIcA An emergenT mArkeT
Mahi L.1, Lemdasni M.2, Houari A.2
1Axelys Sante Affaires Medicales et Recherche Clinique, Paris, France, 2Stratance Health, Rabat, 
France
Objectives: With population of more than 1 Billion, Africa is the world’s second 
largest continent. The transition that African countries are undergoing is a real 
challenge for health care authorities. 24% of the global disease burden is accounted 
in Africa. The diseases that prevailed in the 60s and 70s have not completely disap-
peared, tuberculosis is still endemic as well as transmissible diseases like HIV/AIDS 
and Hepatitis still remained as a major problem while some others, such as cancers, 
cardiovascular and metabolic disorders are dramatically increasing, requiring the 
implementation of effective health care programs and leading to an increasing 
demand for drugs treatment. MethOds: Inventory of the potential of Africa in 
clinical research. Results: In 2012, African Pharmaceutical market revenue was 
USD 18 Billion and expected to reach USD 30 Billion by 2016. Established countries in 
both Sub-Saharan and North African countries (South Africa, Nigeria, Cote d’Ivoire, 
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Objectives: In 2011 the budget of the public payer in Poland, National Health Fund 
(NHF) amounted to 58.2 bln PLN. 47.3% of these funds was allocated to fund hospital 
treatment which is based on diagnosis-related groups (DRGs) but also includes 
innovative, expensive drugs (i. a. chemotherapy, orphan). The aim of the paper was 
to identify the existing correlation between hospital morbidity and the average unit 
cost of hospital treatment in various chronic diseases. Comparison of individual 
hospital costs of treatment different chronic diseases with varying degrees of sever-
ity, different course and level of incidence (from common to ultrarare) open the 
possibility of presenting the correlation between morbidity and unitary medical 
costs incurred by the NHF for the treatment of various indications. MethOds: 
The analysis was prepared for 23 therapeutic areas, which were divided into 4 
categories (diseases: common, infectious, pediatric and rare /ultrarare), diversified 
both in terms of severity and morbidity. This choice gave a possibility of comparing 
a wide range of chronic diseases, which have a significant impact on quality of life 
and mortality. The analyzed material included hospital procedures and services 
indicated by the NHF in 2011. Results: Using the Pearson’s linear Correlation test, 
dependence between variables (the average cost of hospitalization and the number 
of patients) for 23 therapeutic areas was assessed. The results showed that the lower 
prevalence (fewer patients with the diagnosis) is connected with the higher average 
unit cost of treatment. cOnclusiOns: In Poland, among all studied diseases the 
most expensive was the individual treatment of patients diagnosed with ultrarare 
diseases (i. a. Lysosomal storage diseases). Chronic ischemic heart disease, hyper-
tension and diabetes mellitus were associated with the largest number of annual 
hospitalizations and globally were the most cost-intensive for NHF. At the same 
time hypertension is associated with the lowest average unit cost of hospitalization 
among all studied diseases.
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PATIenT rePorTed ouTcomes And THeIr relevAnce In reImbursemenT 
decIsIons
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Objectives: Payers all need evidence of clinical effectiveness, reasonable cost, and 
safety. Although, patient-reported outcomes (PROs) are an important component of 
this evidence it is not always clear which PROs to use and reliance on an incorrect 
PRO can have negative consequences. The objective was to describe the factors 
determining which PROs are most likely to meet payer evidence needs. MethOds: 
A structured discussion of factors influencing PRO choice was held between experts 
in late phase studies, evidence review, and economic modelling. These were then 
validated against a sample of published reimbursement decisions across multiple 
disease areas. Results: Focus of most questions is on whether to use a generic, 
disease-specific or novel measure. Disease specific PROs are very frequently of value 
in demonstrating clinical effectiveness and may be the standard clinical outcome. 
For example, migraine studies include pain assessment and headache frequency. To 
facilitate Payers’ decision making generic PROs such as EQ-5D and SF-36 are com-
monly used for assessing quality of life (QoL). However these instruments may not 
be reliable in disease areas characterised by focal impacts on patient wellbeing. For 
example, pain is only a small component of the SF-36 consequently changes in pain 
levels cannot be measured with great precision and the extreme effects of pain may 
be missed when generating estimates of utility. cOnclusiOns: When choosing a 
PRO, it is important to consider the disease, treatment and payer reimbursement 
decision context. Disease specific QoL measures may be more sensitive than a 
generic tool but may also need mapping to a general QoL measure. Acceptance will 
be contingent on the existence of robust evidence either from published literature 
or additionally collected data. Reviews of previous HTA submissions and payer deci-
sions help identify requirements / standard practices in key markets and identify 
common criticisms or problems.
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PHArmAceuTIcAl secTor To IncreAse effecIency And recovery  
of greek HeAlTH cAre sysTem
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Objectives: Greece is under a very tough and strict memorandum enforced by 
the European Union that has designed and applied austerity measures in order 
to save Greek economy and minimizes its public debt. Also the Greek Heath care 
system should be improved, upgraded or redesigned from scratch in order to be 
more flexible and more efficient. The legislative intervention made by the European 
Union and the memorandum in Greek Heath Care system and the Pharmaceutical 
market constituted legislative framework for the Greek Heath Care and the 
Pharmaceutical sector. MethOds: Data on total pharmaceutical expenditures 
from 2009-2011, some of them until 2012 were obtained from Hellenic Association 
of Pharmaceutical Companies. They were analyzed using basic statistical methods 
of observing. Results: In nearly all observed parameters was recorded their low-
ering. Total pharmaceutical expenditures per capita Δ x2009-2011= -20%, x2011= 5.073 
mil € , pharmaceutical expenditure as% of health expenditure Δ x2009-2011= -6,5%, 
x2011= 24,1%, pharmaceutical expenditure as % of GDP Δ x2009-2011= -11,1%, x2011= 
2,4%, private pharmaceutical expenditure Δ x2009-2011= -13%, x2011= 1.094 mil € , pri-
vate pharmaceutical expenditure per capita Δ x2009-2011= -13,5%, x2011= 96 € , public 
pharmaceutical expenditure Δ x2009-2012= -36,8%, x2012= 3.215 € , public pharmaceu-
